In the TCGA cohort, also no significant difference was seen for OS (only n = 10 patients deceased in total), but a low expression in tumor samples correlated with a significantly shorter BCR-free survival (p = 0.043) and a shorter progression-free interval (p < 0.001) (Figure 3c,d). This evidence concerns the gene BCR and neoplasm.